Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma a randomised, double-blind phase III trial

Publication at Faculty of Medicine in Hradec Králové |

2007

Background vascular endothelial growth factor(VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma.